Therefore, these results, regarding 2-arylmethyl-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs, are expected for the development of anticancer agents against PTEN-deficient and EGFR-overexpressing cancer. The gene discussed is EGFR; the disease is cancer.